Bartley J. Madden



Free To Choose Medicine brings competition to the FDA's regulatory monopoly on access to new drugs by providing an alternative track for access to new drugs – a track that uses Internet-based, up-to-date information enabling patients and doctors to make informed decisions.  Patients become the ultimate beneficiaries of consumer choice and competition.

A market-based approach to FDA reform—Free To Choose Medicine (FTCM)—was developed in a series of journal articles, including CATO’s Regulation (2004), Cancer Biotherapy & Radiopharmaceuticals (2005), Medical Hypotheses (2009), and the Federalist Society’s Engage (2013). This work is summarized in my book Free To Choose Medicine: Better Drugs Sooner at Lower Cost, 2nd edition (2012).




Amazon link click here


Click here for
“In Defense of Free To
Choose Medicine”




“Madden’s market-based solution appeals to economists like me who are keenly aware of the critical importance of institutional design for a system to promote decentralized responses close to the local knowledge that is available to physicians and their patients, but not to the FDA. This book is fundamentally bipartisan and should be read in that spirit.”

Vernon L. Smith
Nobel Laureate in Economics


Click here for
PowerPoint summary.



Click here for "Allowing patients to choose could save billions."

Click here for “President Trump’s FDA nominee could mean better drugs sooner at lower cost.”

Click here for an article “Free To Choose Medicine and Right To Try.”  It provides a concise summary of Free To Choose Medicine, including an explanation of how FTCM solves the big problems with implementation of Right To Try state legislation.

An early version of FTCM was distributed in a Japanese booklet and played a role in Japan’s passage of legislation in 2013 that implemented FTCM principles for regenerative medicine drugs. A Forbes op-ed (December 1, 2015) with the economist Vernon Smith, “Give the FDA Some Competition with Free To Choose Medicine,” click here, highlights the benefits from FTCM and the importance of Japan’s market-based approach. For more information on this topic, click here.




Click here, "Medicine: Who Should Make Choices for You?" - An alternative to the FDA system




Click here, "The Pathway to Faster Cures: When it comes to life-saving drugs, we need more than modest reform"

Click here, "Tomorrow's Cures Today: Let's liberate medicine in America. Here's our version of health for the 21st century."




PBS TV interview, click here for Part 1 and here for Part 2

Click here for a four minute video focused on retired Navy Lt. Commander Matt Bellina and his fight for freedom to access the most innovative but not-yet-approved drugs to slow the progression of ALS.




Copyright © 2017 Learning What Works, Inc.